"Oximes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that contain the radical R2C=N.OH derived from condensation of ALDEHYDES or KETONES with HYDROXYLAMINE. Members of this group are CHOLINESTERASE REACTIVATORS.
Descriptor ID |
D010091
|
MeSH Number(s) |
D02.092.570.665
|
Concept/Terms |
Oximes- Oximes
- Hydroxyimino Compounds
- Compounds, Hydroxyimino
|
Below are MeSH descriptors whose meaning is more general than "Oximes".
Below are MeSH descriptors whose meaning is more specific than "Oximes".
This graph shows the total number of publications written about "Oximes" by people in this website by year, and whether "Oximes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1995 | 0 | 1 | 1 |
1996 | 0 | 1 | 1 |
1997 | 0 | 3 | 3 |
1999 | 1 | 0 | 1 |
2003 | 1 | 0 | 1 |
2004 | 0 | 1 | 1 |
2008 | 1 | 0 | 1 |
2011 | 1 | 0 | 1 |
2012 | 3 | 1 | 4 |
2013 | 6 | 1 | 7 |
2014 | 2 | 2 | 4 |
2015 | 4 | 2 | 6 |
2016 | 2 | 3 | 5 |
2017 | 5 | 4 | 9 |
2018 | 2 | 0 | 2 |
2019 | 2 | 5 | 7 |
2020 | 4 | 3 | 7 |
2021 | 1 | 2 | 3 |
2022 | 0 | 6 | 6 |
2023 | 0 | 2 | 2 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oximes" by people in Profiles.
-
Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2024 Mar; 34(3):336-346.
-
Thyroid Cancer: A Review. JAMA. 2024 02 06; 331(5):425-435.
-
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. Blood. 2023 03 02; 141(9):996-1006.
-
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. Clin Cancer Res. 2023 02 01; 29(3):521-531.
-
Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors. Cancer. 2023 01 01; 129(1):71-81.
-
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023 01 10; 41(2):186-197.
-
Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial. Thyroid. 2022 Oct; 32(10):1184-1192.
-
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). J Immunother Cancer. 2022 06; 10(6).
-
Development of BRAFV600E-positive acute myeloid leukemia in a patient on long-term dabrafenib for multisystem LCH. Blood Adv. 2022 04 26; 6(8):2681-2684.
-
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. J Immunother Cancer. 2022 03; 10(3).